Consistent with this, plasma from PD patients contains more astrocyte-derived GLT-1+ EVs enriched in α-Syn (Wang et al., 2023), suggesting that astrocyte-derived EV content in plasma may serve as a potential biomarker for clinical diagnosis of PD. Here, SLC1A2 is linked to Parkinson disease.